Dengue Virus Subtype 1 & 3 fused Envelope 58kDa Recombinant
The E.coli derived recombinant 58kDa protein is a genetically engineered peptide which is derived from Dengue Type-1 and 3 to be expressed as a fused envelope, each part in this fusion contains 170 a.a (positions 46-217), it is used in ELISA assay. This fusion protein is connected to a 6xHis Tag. Dengue Type-1 and 3 is purified by proprietary chromatographic technique.
Dengue Virus Subtype 1 & 4 fused Envelope 55kDa Recombinant
Dengue Virus Subtype 1 Envelope 15kDa, C-Terminal (Domain III) Recombinant
Dengue Virus Subtype-1 Envelope 22kDa Recombinant
Dengue Virus Subtype 1 Envelope 32kDa Recombinant
Dengue Virus Subtype 1 Envelope 45kDa Recombinant
Dengue Virus Subtype 1 Recombinant, Insect Cells
Recombinant Dengue Virus Subtype 1 produced in Insect Cells is a polypeptide chain containing amino acids 2-395 and having a molecular weight of 44.8kDa. Dengue Envelope-1 is purified by proprietary chromatographic technique.
Dengue Virus Subtype 2 & 4 fused Envelope 52kDa Recombinant
Dengue Virus Envelope 2 Recombinant
Recombinant Dengue Envelope 2 produced in E. coli is a single polypeptide chain containing 126 amino acids (aa 298-400) and having a molecular mass of 13.8kDa. Recombinant Dengue Envelope 2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques
Sterile filtered colorless solution.
Dengue Virus Subtype-2 Envelope 22kDa Recombinant
The E.coli derived recombinant 22 kDa protein is genetically engineered peptide which is derived from Dengue Type-2 Envelope. This region also contains a common antigen for Dengue IgG & IgM. This protein is fused to 6xHis tag.
Dengue is a mosquito-borne viral infection caused by the dengue virus (DENV), which belongs to the Flavivirus genus of the Flaviviridae family . There are four distinct but closely related serotypes of the virus: DEN-1, DEN-2, DEN-3, and DEN-4 . Dengue is classified into three categories: undifferentiated fever, dengue fever (DF), and dengue hemorrhagic fever (DHF) .
The dengue virus is a single positive-stranded RNA virus . It has four serotypes, each with different interactions with antibodies in human blood serum . The virus is primarily transmitted by the Aedes aegypti mosquito, which is active during the day . The virus’s key biological properties include its ability to infect a variety of cell types, including immune cells, and its expression patterns that vary depending on the host’s immune response .
The primary biological function of the dengue virus is to replicate within the host cells. It plays a significant role in immune responses and pathogen recognition. The virus tricks the immune system to evade its defenses and infect more cells . The host’s immune response includes the production of antibodies and activation of T cells, which can sometimes lead to severe immune reactions .
Dengue virus infects cells by binding to receptors on the host cell’s surface and entering through endocytosis . Once inside, the virus releases its RNA into the cytoplasm, where it is translated into viral proteins . These proteins form a replication complex that produces new viral RNA and proteins, which assemble into new virus particles . The virus also interacts with other molecules and cells, leading to the release of cytokines and other immune responses .
The expression and activity of the dengue virus are regulated at multiple levels. Epigenetic modulation of the host genome, transcription of host genes, translation of viral and host mRNAs, post-transcriptional regulation of the host transcriptome, and post-translational modifications of viral proteins all play a role in the virus’s life cycle . These regulatory mechanisms help the virus evade the host’s immune system and ensure efficient replication .
Dengue virus research has led to significant advancements in diagnostic tools and therapeutic strategies. Diagnostic tools include polymerase chain reaction (PCR) tests to detect viral RNA and serological tests to detect antibodies . Therapeutic strategies focus on supportive care, as there is no specific antiviral treatment for dengue . Research is ongoing to develop effective vaccines and antiviral drugs . The introduction of Wolbachia-infected mosquitoes and gene-editing technologies are also being explored as potential control strategies .
The dengue virus plays a crucial role throughout its life cycle, from development to aging and disease. It infects immune system cells, leading to a range of symptoms from mild fever to severe hemorrhagic fever . The virus’s ability to evade the immune system and replicate efficiently within host cells is key to its survival and transmission . Understanding the virus’s life cycle is essential for developing effective control and treatment strategies .